JSJochen Schopohl

Jochen Schopohl

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jochen Schopohl has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Cardiovascular morbidity in patients with suspected Cushing's syndrome. A prospective evaluation of the German Cushing's registry

    by A Oßwald, E Plomer, C Berr, K Ritzel, J Schopohl, F Beuschlein, M Reincke

    Cushing's syndrome is associated with increased cardiovascular morbidity and mortality. Aim of our study was to evaluate patients with suspected Cushing's syndrome regarding cardiovascular risk factors and comorbidities. The prospective phase of the German Cushing's Registry started in 2012. All patients referred to our hospital since October 2012 with the clinical suspicion of Cushing's syndrome were included in this study. Patients were characterized clinically and biochemically in a standardized fashion. Final diagnosis was based on evidence of tumor histology or adrenal insufficiency following surgery (in case of Cushing's syndrome) or longitudinal follow up (rule-out Cushing's syndrome). Cardiovascular risk factors were assessed clinically and biochemically. Of 55 patients, 34 patients were rule-out cases of Cushing's syndrome. 21 patients had confirmed Cushing's syndrome (38%). Of them, 11 had Cushing's disease, 7 had adrenal Cushing's syndrome (including 2 patients with subclinical hypercortisolism) and 3 had ectopic Cushing's syndrome. Regarding the cardiovascular risk profile, patients with confirmed Cushing's syndrome were more often affected by arterial hypertension (100% vs. 67.6%, p = 0.004), hyperlipidemia (66.7% vs. 29.4%, p = 0.007) or diabetes mellitus (47.6% vs. 8.8%, p = 0.001) compared to rule-out Cushing's syndrome cases. Moreover, waist-to-hip ratio was significantly elevated in patients with Cushing's syndrome compared to rule-out Cushing's syndrome cases (median 1.06 (IQR 0.16) vs. median 0.90 (IQR 0.16), p = 0.000). In conclusion, patients with confirmed Cushing's syndrome have a higher cardiovascular risk profile compared to patients with excluded Cushing's syndrome.

  • Somatuline autogel treatment in acromegaly – 1 year data from SOPRANo study

    by S Störmann, J Schopohl, C Bullmann, C Terkamp, J Flitsch, G Stalla, R Finke, M Christ-Crain, A Luger, M Droste, et al.

    Introduction: Somatuline Autogel (ATG) is an injectable, extended-release formulation of the synthetic somatostatin analog (SSA) lanreotide, used for the treatment of acromegaly and NET. Predictive markers for the use of SSA in these indications are important to optimize treatment. Methods: SOPRANo is a non-interventional, multi-center trial, recruiting patients in Germany, Austria and Switzerland. The aim is to evaluate the efficacy and safety of ATG with special focus on predictive markers for long-term treatment success (including early response, somatostatin receptor expression, and lanreotide plasma levels). Patients are eligible for the trial if they have diagnosis of acromegaly, indication for ATG treatment and signed written informed consent. We report here the data of an interim analysis of a 6 months observation period of 45 patients with acromegaly enrolled since June 2012. Results: 45 patients with acromegaly at an age average of 52.0 (± 13.1), 22 of these were male. Mean duration of acromegaly was 6 years (± 10), 86% presented a macroadenoma. Most common co-morbidities were hypertension (76%), diabetes (40%) and pituitary dysfunction (62%). 93% had been pre-treated by surgery, 48% received prior medical treatment. After 6 months of ATG treatment GH values decreased from (median; 25%/75%) 2.4 ng/ml (0.9/16.7) to 0.8 ng/ml (0.3/2.6) and IGF-I level from 251% ULN (129/372) to 124% ULN (78/149). Somatostatin receptor expression was analysed in a subset of 7 patients with a mean expression of g2. Epworth Sleepiness Scale did not change from baseline to 6 months. Ring size decreased by 4 sizes. HbA1c and glucose levels remained stable. Conclusion: SOPRANo represents the first database evaluating the use Lanreotide ATG treatment of acromegalic (and NET) patients from Germany, Austria and Switzerland. Baseline data are in line with the commonly known profile of acromegalic patients. Future analyses will present patients' outcomes in relation to predictive markers.

  • Time from symptoms to diagnosis in Cushing's syndrome: results of the German Cushing Registry in Munich

    by Cm Berr, K Ritzel, A Osswald, J Schopohl, F Beuschlein, M Reincke

    Background: Cushing's syndrome (CS) is considered a rare disease with an estimated incidence of 1 – 3 cases/million people per year. The often subtle onset of symptoms of CS and its overlap with the metabolic syndrome hampers an early diagnosis. Delayed diagnosis, on the other hand, is associated with increased disease burden and adverse outcome. Therefore, the aim of this study was to analyse the median time-to-diagnosis in patients with CS and its subtypes. Methods: Data from 187 CS patients of the Cushing registry database in Munich since 1990 were used for analysis. The mean age at the time of diagnosis was 44.3 ± 15.7yrs (median 42.8, range 11 – 80; 74% female) and the mean BMI was 30.1 ± 6.7 kg/m2 (median 28.6, range 15 – 51 kg/m2). The data was collected from patients' charts and from oral patient interviews. Results: The database contains data of 106 patients (74% female) with Cushing's diseases (CD), 54 patients (85% female) with adrenal CS (AC) and 26 patients (54% female) with ectopic CS (EC). The median time elapsed between onset of symptoms and final diagnosis was 2.0yrs (range < 1 month to 15.7yrs). In male patients it was 1.6yrs (range < 1 month to 15.2yrs), in female 2.0yrs (range < 1 month to 15.2yrs). The median time-to-diagnosis was slightly longer in patients diagnosed before the year 2000 than thereafter (2.1yrs vs. 1.9yrs). The overall median time-to-diagnosis in CD patients was 2.3yrs (range < 1 month to 15.1yrs), in AC 2.0yrs (range < 1 month to 15.7yrs) and in EC 0.49yrs (range < 1 month to 14.8yrs). About 20% of patients were diagnosed after more than 5 years (CD 61%; AC 33%; EC 6%). Conclusion: The median time-to-diagnosis is still unsatisfactory long in our cohort, but these results are in line with the multicentric ERCUSYN study (2 years). Overall, we observe a shorter lag time to diagnosis in patients with EC than in the other two subtypes.


  • CSOM230B2410: Non-interventional study for the generation of long term safety and efficacy data of pasireotide s.c. in patients with Cushing's disease (Post-Authorization Safety Study)

    by J Schopohl, J Aberle, J Fleck, A Pedroncelli, M Droste

    Introduction: With an annual incidence of 0.7 – 2.4 per million, Cushing's disease (CD) is a rare but devastating disease caused by an adrenocorticotropic hormone (ACTH) secreting pituitary adenoma. CD is associated with severe morbidity and mortality and most commonly affects adults aged 20 – 50, primarily females. Pituitary resection of the adenoma is the current first-line therapy for CD, but surgical failure rates are as high as 25 – 30%. Pasireotide (SOM230), a novel somatostatin analogue, exhibits a unique binding profile with high affinity to four of the five known human somatostatin receptor subtypes (sstr1, 2, 3 and 5) and is approved for pharmacological treatment of CD in the EU and U.S. for those patients for whom surgery has failed or is not an option. A phase III study [CSOM230B2305] showed efficacy of pasireotide s.c. in reducing and normalising hypercortisolism. However, since duration and patient numbers are limited, long-term effects could not be fully addressed. Objective: The primary objective of this non-interventional study [CSOM230B2410] is therefore to document the long-term safety and tolerability profile of pasireotide s.c. in patients with CD in a real life setting. Design: This multinational, multi-center post-marketing observational study does not impose a therapy protocol, diagnostic/therapeutic interventions or a visit schedule. Patients ≥18 years with a diagnosis of Cushing's disease and treated with pasireotide s.c. alone or in combination with other therapies will be monitored over a period of 3 years. Treatment is performed according to the investigator's judgment and local prescribing information. All adverse events as well as available demographic, medical history and current medical data will be documented at patients' visits to their site. Additionally, efficacy data will be collected and for documentation of changes in health-related quality of life, patient-reported outcome questionnaires (Cushing QoL, EURO QoL) are available.

  • Efficacy and Acceptability of Lanreotide Autogel® 120 mg at Different Dose Intervals in Patients with Acromegaly Previously Treated with Octreotide LAR

    by J. Schopohl, C. J. Strasburger, D. Caird, K. Badenhoop, F. Beuschlein, M. Droste, U. Plöckinger, S. Petersenn

    Objective: To assess the efficacy of different dosing intervals of lanreotide, Somatuline Autogel® (Lan-ATG) 120 mg in patients with acromegaly, previously treated with octreotide, long-acting release (Oct-LAR). Patients and study design: Patients previously on Oct-LAR 10, 20, or 30 mg were switched to 6 repeated deep subcutaneous injections of Lan-ATG 120 mg at intervals of 56, 42, or 28 days, respectively. After the third injection, dose intervals were adjusted on the basis of insulin-like growth factor 1 (IGF-1) levels. Results: The ITT (Intention To Treat) population comprised 35 patients who received at least one dose of study medication and at least one post-baseline efficacy assessment. Overall, 62.9% (n=22) of patients had normalised IGF-1 levels with Lan-ATG at study end (one injection interval after the 6th injection of Lan-ATG), which was similar to the proportion at baseline (60.0% [n=21]). QoL did not change from baseline to study end. Patient preference for Lan-ATG was highest in the 56-day dosing interval group: 71%, 54% and 41% of the patients in the 56, 42 and 28 day groups, respectively, expressed a preference for treatment with Lan-ATG (preference for Oct-LAR: 29%, 9% and 35%, respectively, while the remainder had no preference). Conclusion: Lan-ATG 120 mg injected at intervals of 56, 42 and 28 days provided equivalent hormonal control and QoL to Oct-LAR 10, 20 and 30 mg injected every 28 days, respectively. The proportion of patients preferring Lan-ATG treatment was greater in the longer injection interval groups.


  • Effect of growth hormone (hGH) replacement therapy on physical work capacity and cardiac and pulmonary function in patients with hGH deficiency acquired in adulthood.

    by R Nass, R M Huber, V Klauss, O A Müller, J Schopohl, C J Strasburger

    The effects of 6 months of replacement therapy with recombinant human GH (hGH) on physical work capacity and cardiac structure and function were investigated in 20 patients with hGH deficiency of adult onset in a double blind, placebo-controlled trial. The GH dose of 12.5 micrograms/kg BW was self-administered daily sc. Oxygen consumption (VO2), CO2 production, and ventilatory volumes were measured during exercise on a bicycle spiroergometer. M-Mode echocardiography was performed using standard techniques. The VO2 max data, expressed per kg BW (mL/min.kg BW) showed a significant increase from 23.2 +/- 2.4 to 30.0 +/- 2.3 (P < 0.01) in the hGH-treated group, whereas the VO2 max data, expressed per lean body mass (milliliters per min/kg lean body mass) did not change significantly in either group. Maximal O2 pulse (milliliters per beat) increased significantly from 15.2 +/- 5.6 to 19.6 +/- 3.3 mL/beat (P < 0.01), but remained constant in the placebo group. The maximal power output (watts +/- SE) increased significantly (P < 0.01) from 192.5 +/- 13.5 to 227.5 +/- 11.5 in the hGH-treated group, but remained constant in the placebo group. Cardiac structure (left ventricular posterior wall, interventricular septum thickness, left ventricular mass, left ventricular end-systolic dimension, and left ventricular end-diastolic dimension) as well as echocardiographically assessed cardiac function did not change significantly after 6 months of treatment in either group. We conclude that hGH replacement in hGH-deficient adults improves oxygen uptake and exercise capacity. These improvements in pulmonary parameters might be due to an increase in respiratory muscle strength and partly to the changes in muscle volume per se observed during hGH replacement therapy. Furthermore, an increased cardiac output might contribute to the improvement in exercise performance during hGH treatment. According to our data, hGH replacement therapy leads to an improvement of exercise capacity and maximal oxygen uptake, but has no significant effect on cardiac structure.


    • 1 August 1993
      • Vol. 34  (8) , 733-40

    [Imaging procedures in hypothalamic-hypophyseal diseases].

    by J Schopohl, T Vogl, C J Strasburger